Weight-loss startup bets against GLP-1 drugs
The obesity drug market is dominated by one type of medicine. A new startup is wagering that a better approach exists, one that does not target the receptor everyone else is chasing.
GLP-1 receptor agonists (drugs that activate the GLP-1 receptor, a protein involved in regulating appetite and blood sugar) such as semaglutide have rapidly become the dominant approach to obesity treatment. Nearly every startup in the sector is developing its own GLP-1 variant. Mwyngil Therapeutics is not. The company is searching for ways to promote weight loss through a different biological target.
Why take a different path?
CEO Luba Greenwood told STAT News she is not interested in another GLP-1 copycat. Her reasoning: the scientific challenge is greater, and so is the potential value if it succeeds. Which alternative biological target Mwyngil is pursuing has not yet been disclosed. The company is in an early research phase with no clinical results yet available.
From a longevity perspective, this is relevant because of the strong relationship between obesity and aging. Excess weight increases the risk of a range of age-related conditions: cardiovascular disease, type 2 diabetes, certain cancers, and cognitive decline. GLP-1 drugs have also shown effects beyond weight loss in studies, including reductions in inflammatory markers and potentially cardioprotective effects. Whether a non-GLP-1 approach could achieve comparable broad benefits remains an open question.
A bold scientific gamble
The pharmaceutical industry largely follows paths with proven results. Alternative targets for weight management have long appeared in the scientific literature, but few have crossed the clinical threshold. Mwyngil’s strategy is scientifically interesting but early-stage: no clinical data are available yet. This article is based on journalistic reporting, not published research.
Want to research this yourself?
Search for example:
- obesity pharmacological target non-GLP-1 | appetite regulation metabolic signaling pathways | weight management age-related disease